PharmaCyte Biotech, Inc.
PMCB
$0.94
$0.044.34%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.45% | -35.79% | -14.64% | -51.66% | -24.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.41% | -33.15% | -10.66% | -48.62% | -21.53% |
| Operating Income | -24.41% | 33.15% | 10.66% | 48.62% | 21.53% |
| Income Before Tax | -404.76% | -135.69% | 772.47% | -391.57% | -152.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -404.76% | -135.69% | 772.47% | -391.57% | -152.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -404.76% | -135.69% | 772.47% | -391.57% | -152.68% |
| EBIT | -24.41% | 33.15% | 10.66% | 48.62% | 21.53% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -219.70% | -156.34% | 620.15% | 33.00% | -50.39% |
| Normalized Basic EPS | -384.40% | -581.82% | -138.40% | 720.00% | 15.03% |
| EPS Diluted | -219.70% | -156.34% | 620.15% | 33.00% | -50.39% |
| Normalized Diluted EPS | -384.40% | -581.82% | -138.40% | 720.00% | 15.03% |
| Average Basic Shares Outstanding | -11.01% | -13.61% | -17.91% | -19.14% | -12.87% |
| Average Diluted Shares Outstanding | -11.01% | -13.61% | -17.91% | -19.14% | -12.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |